

## **Clustering identifies endotypes of traumatic brain injury in an intensive care cohort: a CENTER-TBI study**

Akerlund, C.A.I.; Holst, A.; Stocchetti, N.; Steyerberg, E.W.; Menon, D.K.; Ercole, A.; ...; CENTER-TBI Participants Investigat

## **Citation**

Akerlund, C. A. I., Holst, A., Stocchetti, N., Steyerberg, E. W., Menon, D. K., Ercole, A., & Nelson, D. W. (2022). Clustering identifies endotypes of traumatic brain injury in an intensive care cohort: a CENTER-TBI study. *Critical Care*, *26*(1). doi:10.1186/s13054-022-04079-w

Version: Publisher's Version License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/) Downloaded from: <https://hdl.handle.net/1887/3564525>

**Note:** To cite this publication please use the final published version (if applicable).

## **RESEARCH**

## **Open Access**



# Clustering identifes endotypes of traumatic brain injury in an intensive care cohort: a CENTER-TBI study

Cecilia A. I. Åkerlund<sup>1,2\*</sup>, Anders Holst<sup>2</sup>, Nino Stocchetti<sup>3</sup>, Ewout W. Steyerberg<sup>4</sup>, David K. Menon<sup>5</sup>, Ari Ercole<sup>5,6</sup>, David W. Nelson<sup>1</sup> and the CENTER-TBI Participants and Investigators

## **Abstract**

**Background:** While the Glasgow coma scale (GCS) is one of the strongest outcome predictors, the current classifcation of traumatic brain injury (TBI) as 'mild', 'moderate' or 'severe' based on this fails to capture enormous heterogeneity in pathophysiology and treatment response. We hypothesized that data-driven characterization of TBI could identify distinct endotypes and give mechanistic insights.

**Methods:** We developed an unsupervised statistical clustering model based on a mixture of probabilistic graphs for presentation (<24 h) demographic, clinical, physiological, laboratory and imaging data to identify subgroups of TBI patients admitted to the intensive care unit in the CENTER-TBI dataset (*N*=1,728). A cluster similarity index was used for robust determination of optimal cluster number. Mutual information was used to quantify feature importance and for cluster interpretation.

**Results:** Six stable endotypes were identifed with distinct GCS and composite systemic metabolic stress profles, distinguished by GCS, blood lactate, oxygen saturation, serum creatinine, glucose, base excess, pH, arterial partial pressure of carbon dioxide, and body temperature. Notably, a cluster with 'moderate' TBI (by traditional classifcation) and deranged metabolic profle, had a worse outcome than a cluster with 'severe' GCS and a normal metabolic profle. Addition of cluster labels signifcantly improved the prognostic precision of the IMPACT (International Mission for Prognosis and Analysis of Clinical trials in TBI) extended model, for prediction of both unfavourable outcome and mortality (both  $p < 0.001$ ).

**Conclusions:** Six stable and clinically distinct TBI endotypes were identifed by probabilistic unsupervised clustering. In addition to presenting neurology, a profle of biochemical derangement was found to be an important distinguishing feature that was both biologically plausible and associated with outcome. Our work motivates refning current TBI classifcations with factors describing metabolic stress. Such data-driven clusters suggest TBI endotypes that merit investigation to identify bespoke treatment strategies to improve care.

*Trial registration*

The core study was registered with ClinicalTrials.gov, number [NCT02210221,](https://clinicaltrials.gov/ct2/show/NCT02210221) registered on August 06, 2014, with Resource Identifcation Portal (RRID: SCR\_015582).

\*Correspondence: cecilia.akerlund@ki.se

<sup>2</sup> School of Electrical Engineering and Computer Science, KTH Royal Institute of Technology, Stockholm, Sweden

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/.](http://creativecommons.org/licenses/by/4.0/) The Creative Commons Public Domain Dedication waiver ([http://creativeco](http://creativecommons.org/publicdomain/zero/1.0/) [mmons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data. **Keywords:** Traumatic brain injury, Endotypes, Intensive care unit, Critical care, Unsupervised clustering, Machine learning

## **Background**

Traumatic brain injury (TBI) is a heterogeneous disease with a wide variety of injury mechanisms and tissue pathologies, afecting people at all stages of life. It is one of the leading causes of mortality and morbidity in young individuals globally, with a leading global cause being road traffic incidents  $(RTI)$  [\[1](#page-14-0)]. Additionally, the incidence of TBI in older patients is increasing as this multi-morbid and fall-prone population increases in prevalence [\[2](#page-14-1)].

Although mortality from TBI has decreased over the last 30 years, the proportion of patients with favourable outcomes have remained relatively unchanged [\[2](#page-14-1)[–4](#page-14-2)], despite developments such as intracranial pressure (ICP) monitoring [\[5](#page-14-3)]. A recent report identifed large variation in TBI management in a European multi-centre cohort, without a corresponding variation in outcomes [\[6](#page-14-4)]. While it is possible that these management variations truly had no impact on outcome, this result could also be due to a substantial heterogeneity of the disease masking treatment efect in relevant subgroups. Due to lack of high-quality evidence, variations in treatment strategies are based largely on local strategies rather than mechanistically aligned to injury types [\[7](#page-14-5)[–9](#page-14-6)]. A better characterization of patients could allow discrimination into more specifc and biologically relevant sub-groups based on clinical, biomarker, pathoanatomic, and physiological features.

This approach could provide a basis for determining whether specifc treatments and interventions might be more efective in some of these sub-groups [[7,](#page-14-5) [9–](#page-14-6) [11\]](#page-14-7). However, implementation of such individualized treatment strategies relies on the identifcation of robust and relevant endotypes. Endotypes are subtypes of a clinical condition or syndrome, which can be characterized by distinct pathophysiology, and have an implicit likelihood of variation in response to therapies. This approach was first used to describe subgroups in asthma [[12\]](#page-14-8), but has now been used in other conditions [[13\]](#page-14-9). Recently, unsupervised machine learning methods have been successful in discovering subgroups and endotypes with specifc treatment-responses in diseases such as acute respiratory distress syndrome (ARDS) and sepsis in the intensive care unit (ICU) [[14](#page-14-10), [15\]](#page-14-11).

The current classification of TBI simply as 'mild', 'moderate' and 'severe' is based on the level of consciousness at presentation, assessed using the Glasgow coma scale (GCS). While this is well known to be an important predictor of outcome and easy to operationalize, it is also clearly an overly simplistic description of such a complex disease and unlikely to be aligned with underlying pathobiology. As such, this simple classifcation provides a poor substrate from which to individualise care. Furthermore, it limits research into personalised medicine as populations stratifed in this way retain biological heterogeneity and therefore are likely to be diverse in terms of their treatment response.

Instead, we hypothesize the existence of distinct clinically and/or physiologically determinable endotypes in patients with TBI requiring ICU treatment and that these may be described not only by canonical measures of injury severity, such as Glasgow Coma Scale (GCS), but also by pathophysiology. We further hypothesize that these parameters might present complex or nonlinear relationships to disease course and outcome, so that unsupervised/machine learning methods may be required to reveal underlying relationships between parameters. The aim of this study is not primarily to describe endotypes associated with outcome, but to describe endotypes that could motivate tailored treatments in the future, and potentially lead to improved outcome in patients with TBI.

## **Methods**

## **Patient and feature selection**

All patients over 18 years old enrolled in the multinational study Collaborative European Neuro Trauma Efectiveness Research in TBI (CENTER-TBI) ICU cohort  $(N=2006)$  were included in the study, between 2014 and 2018 [[4,](#page-14-2) [10](#page-14-12)], Additional fle [1:](#page-11-0) Fig S1. All patients met the general inclusion criteria for CENTER-TBI (clinical diagnosis of TBI, presentation at hospital within 24 h from injury, and a clinical need for a CT scan) and were admitted to the ICU immediately after hospital admission. More than 2000 parameters were collected for each patient. Of these, a total of 35 early features were selected, including those in the core IMPACT prediction model for TBI [\[16](#page-14-13)] and features identifed to be of clinical interest. The data and variables in the CENTER-TBI database were based on the synthesis of current knowledge of TBI in concert with much of European and Northern American expertise. The variables chosen for this analysis were early features with known or plausible relations with outcome, or deranged physiology (Table [1](#page-3-0)) as judged by clinicians with extensive neurointensive

## <span id="page-3-0"></span>**Table 1** Features included in the model



All values were collected at admission

*ASA-PS* American society of anesthesiologists physical status classifcation; *BMI* body mass index; *GCS* Glasgow coma scale; *MAP* mean arterial pressure; *SpO2* oxygen saturation; *PaO<sub>2</sub>* arterial partial pressure of oxygen; *PaCO<sub>2</sub>* arterial partial pressure of carbon dioxide; *TAI* traumatic axonal injury; *EDH* epidural hematoma; *aSDH* acute subdural hematoma

\*Feature included in the IMPACT core model

care experience. CT characteristics were extracted from a central imaging review. All selected features were recorded at presentation, i.e., either prehospital, during emergency room (ER) admission or early within the ICU, but no later than 24 h post-injury. Both GCS total and motor sub-score were included, as the total score is of clinical interest and the motor sub-score have shown prediction ability in the IMPACT model. Outcome was represented by the eight-point Glasgow outcome scale extended,  $(GOS-E)$  score, where  $GOS-E$  1 = dead and GOS-E  $8$  = full recovery.

Version 3.0 of the CENTER-TBI dataset was used for this work. Models were created using proprietary lowlevel code in  $C++$  and all other analyses were performed using R version 1.1.453 [[17\]](#page-14-14).

## **The clustering model**

We used a mixture of probabilistic graph models to construct an unsupervised classifer suitable for dealing with the mix of discrete and continuous features with missingness. The univariate probability distributions for all features were modelled as a product model, and compensating factors for each pair of strongly correlated features were included.

To frst determine which features were correlated and therefore would need to be considered jointly, linear correlations between features were examined graphically using the R package corrplot (version 0.84), Fig.  $1$  [\[18](#page-14-15)]. Pairs of strongly correlated features (pH and base excess, pH and arterial partial pressure of carbon dioxide (PaCO<sub>2</sub>), GCS motor and total score, Rotterdam CT score and midline shift, Rotterdam CT score and Fisher classifcation, GCS motor score and pupil response, age and ASA PS-class (American Society of Anesthesiologists physical status classifcation), and age and anticoagulants at baseline) were modelled as bivariate joint Gaussian distributions. Completeness of data is presented in, Additional fle [2](#page-11-1): Table S1.

To estimate the parameters and cluster membership probabilities in our graph mixture model, we used an expectation maximisation  $(EM)$  algorithm  $[19, 20]$  $[19, 20]$  $[19, 20]$  $[19, 20]$  $[19, 20]$ . This is a generalization of the maximum likelihood estimation of incomplete data and ofers a principled, probabilistic approach to the unsupervised clustering of large multivariable datasets without the need for imputation when missingness is present [[20](#page-14-17)]. Conceptually, the EM algorithm is a two-step iterative algorithm: in the expectation (*E*) step, the probability distribution over all clusters for each patient is calculated from the given parameters of the features in the cluster (i.e., the probability for cluster membership for each patient), and the maximization (*M*) step is the re-estimation of parameter distributions in all clusters. These steps are repeated until convergence, giving the most probable separation of clusters given the chosen number of clusters and predictor features. Further mathematical details are described in Additional fle [3](#page-11-2).

## **Determination of number of clusters**

We used a cluster stability to robustly determine the most appropriate number of clusters to choose [\[21](#page-14-18)]. Numbers from three to ffteen clusters were evaluated for stability. This selection was a clinical trade off  $-$  too many clusters might not be clinically relevant, despite the risk that they may represent potentially important separation of phenotypes. However, within this range a methodologically principled optimum may be identifed.

For each number of clusters considered, we created ten different models, using different random seeds. The log-likelihood for each model was calculated, and the model with the highest log-likelihood was selected. This process was repeated twenty times (Fig. [2](#page-5-0)) and cluster similarity was quantifed using a cluster similarity index (CSI) defned as the fraction of patients who were assigned to the same cluster in two models [[21](#page-14-18)]. CSI was calculated between all pairs of the models of the same number of clusters, and median and interquartile range (IQR) was calculated. As the CSI, when numbers of clusters<<number of patients, by nature is higher for lower number of clusters, a penalty for the number of clusters was added by subtracting 1/*n* clusters from all median CSI. The optimal clustering was defined as number of clusters with the highest median CSI



<span id="page-4-0"></span>(representing the most stable number of clusters). When describing the clusters, the model of the optimal number of clusters with the highest log-likelihood was chosen to represent our model.

## **Evaluation of the clusters**

To investigate the importance of each feature for the model, the mutual information (MI) was calculated

between each feature and the cluster labels. The MI represents how well the cluster label is determined by a feature, with respect to how the distributions difer between the clusters. Features were considered to be of value if the MI>0.1. A descriptive analysis of the clusters using these features was undertaken. Univariable logistic regression analysis was performed to determine the pseudo-explained variance between cluster label and



<span id="page-5-0"></span>outcome, and a multivariable regression analysis was performed to investigate if the cluster label could improve predicted outcome over the "International Mission for Prognosis and Analysis of Clinical Trials in TBI" (IMPACT) variables which have been well characterised as predictors in TBI  $[16]$ . For the outcome prediction (but not the clustering), missing values were imputed using the multiple imputation with chained equations (MICE) algorithm in  $R$  [[22\]](#page-14-19). The observed mortality and unfavourable outcome (defned as GOS-E<5) frequencies in all clusters was compared to the IMPACT predicted outcome.

## **Results**

## **Patient characteristics**

278 patients were excluded due to missing Glasgow outcome scale extended (GOS-E) score at 6 months, leaving 1728 patients for the analysis. The mean age was 50.4 years (SD 19.3) and 1269 (73.4%) were male. The most common causes of injury were RTIs (46.5%) and falls  $(43.7%)$ . The overall mortality in the cohort was 22%, and 45% had unfavourable outcomes (defned as Upper Severe Disability or worse according to the GOS-E outcome scale) 6 months post-injury. Based on the IMPACT core model, the overall analysis cohort had a predicted mortality of 31%, and a predicted unfavourable outcome of 51%.

## **Optimal number of clusters**

Applying a penalty of 1/*n* from the median CSI of each number of clusters revealed a peak in median CSI, indicating the highest cluster stability, for 6 clusters, Fig. [3.](#page-6-0) Cluster assignments in twenty randomly generated models of 6 clusters are presented in Fig. [4](#page-7-0), demonstrating the robust reproducibility of our model.

The number of patients in the clusters was 48, 262, 360, 343, 218, and 497, respectively.

## **Importance of features included in the model**

GCS motor score, GCS total score, lactate, oxygen saturation (SpO<sub>2</sub>), creatinine, glucose, base excess, pH, PaCO<sub>2</sub> and body temperature were identified as the most important features in our model with respect to MI. Median values in all clusters are presented in Fig. [5](#page-8-0), Table [2](#page-8-1), and a full list of MI and cluster medians for all features is provided in, Additional fle [4](#page-11-3): Table S2. A description of cluster characteristics is given in Fig. [6](#page-9-0) and Table [3](#page-9-1). The results were interpreted by the authors with extensive academic and clinical neurointensive care experience. The six clusters may generally be described by combinations of GCS score and degrees or patterns of deranged metabolism. Outcome predictions and parameters, as well as injury severity and treatment features which were not used in the clustering, are presented in Table [4](#page-10-0).

## **Relation of clusters to outcome**

Outcome information was not included in the clustering process. In all clusters except Clusters B and C, the IMPACT model overestimated mortality with overestimation ranging from 4 to 7%, but underestimated functional outcome in four of the six clusters, with an underestimation ranging from  $-2$  to  $-15\%$ . By adding the cluster label to the IMPACT extended model variables (age, GCS motor score, pupil reactivity, Rotterdam CT score, presence of traumatic subarachnoid haemorrhage, intraventricular haemorrhage, epidural hematoma, hypoxia, and hypotension), predictions for mortality as well as unfavourable outcome were improved with a small but statistically signifcant increase



<span id="page-6-0"></span>of Nagelkerke pseudo- $R^2$  from 0.42 to 0.44 and from 0.36 to 0.38, respectively  $(p=0.001$  and  $p=2.9\times10^{-5}$ , respectively). The improvement in explained variance was comparable to that achieved by the addition of laboratory values within the original IMPACT model for mortality prediction (Nagelkerke pseudo-*R*<sup>2</sup> 0.42 to 0.44,  $p=3.6\times10^{-5}$ ), and prediction of unfavourable outcome (Nagelkerke pseudo- $R^2$  of 0.36 to 0.37,  $p = 2.1 \times 10^{-4}$ ). These clusters, therefore, appear to represent groups with outcomes that difer in both directions from current prediction models. The relationships of clusters to outcomes and IMPACT predicted outcomes are seen in Table [4](#page-10-0).

## **Discussion**

We have used an EM clustering approach, based on early clinical and laboratory data, that identifed six distinct potential clusters of TBI patients admitted to the ICU. These clusters exhibited distinct systemic metabolic profles defned by combinations of plasma lactate,  $SpO<sub>2</sub>$ , creatinine, glucose, base excess, pH, PaCO<sub>2</sub>, and body temperature, which in combination with GCS, characterizes 6 clinically distinct patient endotypes.

Profles of metabolic derangement may be readily recognized clinically, and arguably contribute to our impression of severity state in TBI patients in the ICU. However, except for blood glucose, the identifed features are not incorporated into current formal



<span id="page-7-0"></span>defnitions of TBI severity or outcome prediction models, although earlier publications have reported improved accuracy adding physiology-based prediction scores, such as APACHE II score (Acute Physiology and Chronic Health Evaluation II) [[23,](#page-14-20) [24\]](#page-14-21).

We hypothesize there to be several diverging mechanisms leading to deranged metabolism in TBI patients that are not fully captured by conventional ICU disease severity metrics, such as APACHE II scores. These may include interplay of secondary and extracranial injury, and concurrent comorbidities. This is the rationale for defining metabolic profiles using several features highly correlated to pH– base excess, PaCO<sub>2</sub>, and lactate that may reflect several intrinsic mechanisms. In Cluster *C*, a deranged metabolic picture appears to refect a general stress response, with high lactate and high blood glucose in more elderly patients prone to insulin resistance. In contrast, Cluster *E* is representative of younger patients displaying tachycardia and relative hypotension, in whom the cause of metabolic compromise is more likely to refect a state of systemic shock, which is more likely to be related to extracranial injury. It must be noted that the endotype with a general stress response is a relatively small subset of patients  $(N=48)$  but may

nevertheless be of clinical importance as it seems likely to result from a distinct pathology. These two metabolic pictures may easily be distinguished clinically and likely beneft from diferent treatment approaches allowing for articulation of broad strategies of care and overall management in endotypic groups.

Although GCS has been shown to be one of the most principal factors in classifcation of TBI [\[16](#page-14-13)], the weakness of GCS alone as a classifer of TBI severity becomes apparent in this study. In Cluster *A*, comprising 28% (*N*=497) of the total number of patients TBI severity would be classified as 'mild' based on GCS. This group was in general characterized by patients who were older with comorbidities and receiving anticoagulant or antiplatelet treatments pre-injury and the cause of ICU admission did not seem to be explained by extracranial injuries, Table [4,](#page-10-0) but may rather have been motivated by a need for clinical observation, something which was highlighted in a previous CENTER-TBI sub-study [\[6](#page-14-4)]. However, the morbidity and treatment burden in this group is substantial: 45% of patients in this cluster were intubated, 15% had ICP monitoring, and 7% died within 6 months post-injury. In addition, Cluster *C*, the cluster with deranged metabolism, had the largest deviation in outcome prediction in comparison with the IMPACT



<span id="page-8-1"></span><span id="page-8-0"></span>**Table 2** Cluster medians and mutual information (MI) for features with MI > 0.1



Data presented as median (interquartile range)

*GCS*, glasgow coma scale; *SpO<sub>2</sub>*, oxygen saturation; *PaCO<sub>2</sub>*, arterial partial pressure of carbon dioxide; *MI*, mutual information



<span id="page-9-1"></span><span id="page-9-0"></span>**Table 3** Narrative description of typical physiological and clinical features of the clusters identifed



*TBI* traumatic brain injury; *DC* decompressive craniectomy; *GCS* glasgow coma scale; *RTI* road trafc incident; *TAI* traumatic axonal injury

model. When compared to Cluster *D* (which comprises patients with severe TBI but without such metabolic derangement), Cluster *C* had a worse outcome, which further supports the impact of assessing the metabolic profle in TBI patients, beyond derangements that are simply explained by extracranial injuries. It may also refect an increased vulnerability of the brain in older patients which is not captured in other factors

associated with severity of brain damage, such as GCS. Although they did not have as complete a description of biochemical derangements in their dataset, Folweiler et al. elegantly showed TBI clustering that did not relate well to 'mild', 'moderate' or 'severe' descriptions of TBI [[25\]](#page-14-22). In our study again, although GCS is here shown to be an important component of endotypes in an ICU cohort, metabolic profles may add additional, clinically

## <span id="page-10-0"></span>**Table 4** Injury severity, outcome and predicted outcome with the IMPACT lab model



Data presented as median (IQR) or *N* (%) if not else is stated

*ISS* injury severity score; *ICP* intracranial pressure; *TIL* therapy intensity level; *GOS-E* glasgow outcome scale extended; *IMPACT* international mission on prognosis and clinical trial design in TBI

important, information as descriptors of TBI severity, and perhaps identify patient groups in which treatment should be individualized.

Surprisingly, neither our model nor earlier endotypic multidimensional descriptions of TBI patients generated by unsupervised machine learning methods have identifed the type of intracranial injuries and CT characteristics as relevant for describing endotypes [\[25](#page-14-22), [26\]](#page-14-23). However, a recent study could identify clusters based solely on CT characteristics [\[27](#page-14-24)], supporting that these factors may play an essential role in understanding the type of injury and determining the need for intracranial surgery, and prediction models using CT fndings such as the Marshall, Rotterdam, Helsinki and Stockholm CT scores do discriminate outcome  $[28-31]$  $[28-31]$  $[28-31]$ . These findings are less evident in multivariable analyses when including GCS and other IMPACT variables as covariates, then contributing approximately only 5% additional pseudovariance toward outcome  $[31, 32]$  $[31, 32]$  $[31, 32]$  $[31, 32]$ . This covariance may be a possible explanation as to why we could not identify CT characteristics as one of the most important discriminative factors between the clusters.

Unsupervised learning is appealing from the point of view of objectivity, but cannot be performed entirely without making certain choices, and requires subsequent interpretation. The number of clusters is a trade-off between not being overwhelmed by multitudes of clusters with small sizes that cannot be interpreted, and very few clusters inherently containing little discriminant information. The identification of six clusters of TBI patients was supported by both the maximal and stable reproducibility represented by a CSI of 80%, as well as a suggestion of clinical relevance. Most clusters were relatively stable across diferent random initializations of the clustering, with the exception of cluster *B* and *C*, both representing patients with intermediate GCS, Fig. [4.](#page-7-0) By nature, more extreme patient characteristics and their corresponding clusters tend to be more stable while the intermediate level characteristics and clusters are less stable. Most patients were clearly assigned to a stable cluster, as seen in, Additional fle [1:](#page-11-0) Fig. S2. It is

unrealistic to expect perfectly stable cluster assignment in heterogenous real world data with any method, particularly with random assignment to initial clusters. We believe our evaluation of model robustness to be an important and generalisable strength of our work.

In this study we are naturally limited by the variables collected. These represent nevertheless the compound experience and knowledge of a large cohort of leading TBI researchers and clinicians during the planning of the study. However, additional variables such as future biomarkers and genetic profles may be needed to sufficiently describe patient heterogeneity in TBI. Furthermore, despite that the object of clustering is to identify reproducible compound and complex patterns, it does not weigh variables toward severity as would for example an experienced clinician and represents a general limitation of unsupervised leaning.

The aim of this study was not primarily to create clusters of TBI patients toward outcome prediction, but to identify clinically relevant and distinct endotypes of patients, which could potentially infer personalization of future treatment strategies. Current TBI therapy is based on limited high-level evidence, leading to between-centre treatment variability beyond that of case mix [[7,](#page-14-5) [9](#page-14-6), [33](#page-15-0)]. Further discrimination of patient heterogeneity has been identifed as necessary to further the feld [[7,](#page-14-5) [9\]](#page-14-6). Prediction of both mortality and functional outcome using the IMPACT extended model was signifcantly improved by adding cluster labels. That the metabolic cluster profiles identified in this study are signifcantly associated with outcome, despite an unsupervised clustering method (not including outcome), supports a biological underpinning and motivates further investigation. A natural progression will be to investigate if the clusters described in this study exhibit a diferent temporal trajectories in the ICU or, in analogy with work within the feld of ARDS [[14](#page-14-10)] respond differently to treatments in earlier RCTs.

## **Conclusions**

While GCS is a strong predictor of TBI outcome, an admission metabolic profle incorporating hypothermia, lactatemia, blood glucose,  $SpO<sub>2</sub>$ , PaCO<sub>2</sub>, pH, base excess and creatinine allows for a more holistic description of patients with TBI who require ICU care. Synthesis of these data using an unsupervised clustering method reveals six distinct and stable subgroups of TBI patients. Although not a key objective of the analysis, we found that clusters contain information that can provide a signifcantly better explanation of outcome beyond that provided by variables used in current outcome prediction models. The addition of biomarkers and genetics may improve this endotypic classifcation further. Future studies should address replication and validation of this approach, but our work provides an important starting point from which to devise and prospectively investigate therapeutic strategies individualised to more biologically relevant groups or TBI patients.

## **Abbreviations**

APACHE II score: Acute physiology and chronic health evaluation II score; ARDS: Acute respiratory distress syndrome; ASA-PS class: American society of anesthesiologists physical status classifcation; aSDH: Acute subdural hematoma; BMI: Body mass index; CENTER-TBI: Collaborative European neuro trauma efectiveness research in TBI; CSI: Cluster similarity index; DC: Decompressive craniectomy; EDH: Epidural hematoma; EM: Expectation maximization; GCS: Glasgow coma scale; GOS-E: Glasgow outcome scale extended; ICU: Intensive care unit; ICP: Intracranial pressure; IMPACT: International mission for prognosis and analysis of clinical trials in TBI; IQR: Interquartile range; ISS: Injury severity score; MAP: Mean arterial pressure; MI: Mutual Information; MICE: Multiple imputation with chained equations; PaCO<sub>2</sub>: Arterial partial pressure of carbon dioxide; PaO<sub>2</sub>: Arterial partial pressure of oxygen; RTC: Road traffic collision; RTI: Road traffic incident; SpO<sub>2</sub>: Oxygen saturation; TAI: Traumatic axonal injury; TBI: Traumatic brain injury; TIL: Therapy intensity level; tSAH: Traumatic subarachnoid haemorrhage.

## **Supplementary Information**

The online version contains supplementary material available at [https://doi.](https://doi.org/10.1186/s13054-022-04079-w) [org/10.1186/s13054-022-04079-w.](https://doi.org/10.1186/s13054-022-04079-w)

<span id="page-11-1"></span><span id="page-11-0"></span>Additional file 1: Figures of flowchart of patient selection and cluster assignment probabilities.

<span id="page-11-2"></span>**Additional fle 2**: Table of completeness of all features in the dataset.

<span id="page-11-3"></span>**Additional fle 3**: Additional details of the clustering method.

**Additional fle 4**: Table of Cluster means and overall means, min, max and standard deviation of all features.

#### **Acknowledgements**

Data for the CENTER-TBI study was collected through Quesgen e-CRF (Quesgen Systems Inc, USA), hosted on the INCF platform and extracted via the INCF Neurobot tool (INCF, Sweden). Version 3.0 of the CENTER-TBI dataset was used in this manuscript.

The authors would like to thank the patients for their participation in the CENTER-TBI study, and all CENTER-TBI Participants and Investigators for taking part in the collection and sharing their valuable expertise: Cecilia Åkerlund<sup>1</sup>, Krisztina Amrein<sup>7</sup>, Nada Andelic<sup>8</sup>, Lasse Andreassen<sup>9</sup>, Audny Anke<sup>10</sup>,Anna Antoni<sup>11</sup>,Gérard Audibert<sup>12</sup>,Philippe Azouvi<sup>13</sup>,Maria LuisaAzzolini<sup>14</sup>, Ronald Bartels<sup>15</sup>,Pál Barzó<sup>16</sup>,Romuald Beauvais<sup>17</sup>,Ronny Beer<sup>18</sup>,Bo-Michael Bellander<sup>19</sup>,Antonio Belli<sup>20</sup>,Habib Benali<sup>21</sup>,Maurizio Berardino<sup>22</sup>,Luigi Beretta<sup>14</sup>,Morten Blaabjerg<sup>23</sup>,Peter Bragge<sup>24</sup>,Alexandra Brazinova<sup>25</sup>,Vibeke Brinck<sup>26</sup>,Joanne Brooker<sup>27</sup>,Camilla Brorsson<sup>28</sup>,Andras Buki<sup>29,30</sup>,Monika Bullinger<sup>31</sup>,Manuel Cabeleira<sup>32</sup>,Alessio Caccioppola<sup>33</sup>,Emiliana Calappi<sup>33</sup>, Maria RosaCalvi<sup>14</sup>, Peter Cameron<sup>34</sup>, Guillermo CarbayoLozano<sup>35</sup>, Marco Carbonara<sup>33</sup>, Simona Cavallo<sup>22</sup>, Giorgio Chevallard<sup>36</sup>, Arturo Chieregato<sup>36</sup>,Giuseppe Citerio<sup>37,38</sup>,Hans Clusmann<sup>39</sup>,Mark Coburn<sup>40</sup>,Jonathan Coles<sup>41</sup>, Jamie D.Cooper<sup>42</sup>, Marta Correia<sup>43</sup>, Amra Čović<sup>44</sup>, Nicola Curry<sup>45</sup>, Endre Czeiter<sup>29,30</sup>, Marek Czosnyka<sup>32</sup>, Claire DahyotFizelier<sup>46</sup>, Paul Dark<sup>47</sup>, Helen Dawes<sup>48</sup>, Véronique DeKeyser<sup>49</sup>, Vincent Degos<sup>21</sup>, Francesco DellaCorte<sup>50</sup>, Hugo denBoogert<sup>15</sup>, Bart Depreitere<sup>51</sup>,Đula Đilvesi<sup>52</sup>, Abhishek Dixit<sup>53</sup> Emma Donoghue<sup>27</sup>, Jens Dreier<sup>54</sup>, GuyLoup Dulière<sup>55</sup>, Ari Ercole<sup>53</sup>, Patrick Esser<sup>53</sup>,Erzsébet Ezer<sup>61</sup>,Martin Fabricius<sup>62</sup>,Valery L.Feigin<sup>63</sup>, Kelly Foks<sup>59</sup>,Shirin Frisvold<sup>60</sup>, Alex Furmanov<sup>61</sup>, Pablo Gagliardo<sup>62</sup>, Damien Galanaud<sup>21</sup>, Dashiell Gantner<sup>34</sup>, Guoyi Gao<sup>63</sup>, Pradeep George<sup>64</sup>, Alexandre Ghuysen<sup>65</sup>, Lelde Giga<sup>66</sup>,Ben Glocker<sup>67</sup>,Jagoš Golubovic<sup>52</sup>, Pedro A. Gomez<sup>68</sup>,Johannes Gratz<sup>69</sup>,Benjamin Gravesteijn<sup>70</sup>,Francesca Grossi<sup>50</sup>,Russell L.Gruen<sup>71</sup>, Deepak Gupta<sup>72</sup>,Juanita A.Haagsma<sup>70</sup>, lain Haitsma<sup>73</sup>,Raimund Helbok<sup>18</sup>,Eirik

Helseth<sup>74</sup>,Lindsay Horton<sup>75</sup>, Jilske Huijben<sup>70</sup>, Peter J.Hutchinson<sup>76</sup>, Bram Jacobs<sup>77</sup>,Stefan Jankowski<sup>78</sup>,Mike Jarrett<sup>26</sup>,Jiyao Jiang<sup>64</sup>,Faye Johnson<sup>79</sup>,Kelly Jones58,Mladen Karan52,Angelos G.Kolias74, Erwin Kompanje80,Daniel Kondziella<sup>57</sup>, Evgenios Kornaropoulos<sup>53</sup>, LarsOwe Koskinen<sup>81</sup>, Noémi Kovács<sup>82</sup>,Ana Kowark<sup>83</sup>,Alfonso Lagares<sup>68</sup>,Linda Lanyon<sup>64</sup>,Steven Laureys<sup>84</sup>,Fiona Lecky<sup>85,86</sup>,Didier Ledoux<sup>84</sup>,Rolf Lefering<sup>87</sup>,Valerie Legrand<sup>88</sup>,Aurelie Lejeune<sup>89</sup>,Leon Levi<sup>90</sup>,Roger Lightfoot<sup>91</sup>,Hester Lingsma<sup>70</sup>,Andrew I. R. Maas<sup>49</sup>, Ana M. CastañoLeón<sup>68</sup>,Marc Maegele<sup>92</sup>,Marek Majdan<sup>25</sup>,Alex Manara<sup>91</sup>,Geoffrey Manley<sup>94</sup>,Costanza Martino<sup>95</sup>,Hugues Maréchal<sup>55</sup>,Julia Mattern<sup>96</sup>,Catherine McMahon<sup>97</sup>,Béla Melegh<sup>98</sup>,David Menon<sup>53</sup>,Tomas Menovsky<sup>49</sup>,Ana Mikolic<sup>70</sup>,Benoit Misset<sup>84</sup>,Visakh Muraleedharan<sup>64</sup>,Lynnette Murray<sup>34</sup>,Ancuta Negru<sup>99</sup>,David Nelson<sup>1</sup>,Virginia Newcombe<sup>53</sup>,Daan Nieboer<sup>70</sup>,József Nyirádi<sup>7</sup>,Otesile Olubukola<sup>85</sup>,Matej Oresic<sup>100</sup>,Fabrizio Ortolano<sup>33</sup>,Aarno Palotie<sup>101,102,103</sup>,Paul M.Parizel<sup>104</sup>, JeanFrançois Payen<sup>105</sup>, Natascha Perera<sup>17</sup>, Vincent Perlbarg<sup>21</sup>, Paolo Persona<sup>106</sup>, Wilco Peul<sup>107,108</sup>, Anna Piippo-Karjalainen<sup>109</sup>, Matti Pirinen<sup>101</sup>, Dana Pisica<sup>70</sup>,Horia Ples<sup>99</sup>,Suzanne Polinder<sup>70</sup>,Inigo Pomposo<sup>35</sup>,Jussi P.Posti<sup>110</sup>, Louis Puybasset<sup>111</sup>, Andreea Radoi<sup>112</sup>, Arminas Ragauskas<sup>113</sup>, Rahul Raj<sup>109</sup>,Malinka Rambadagalla<sup>114</sup>,Isabel RetelHelmrich<sup>70</sup>, Jonathan Rhodes<sup>115</sup>,Sylvia Richardson<sup>116</sup>,Sophie Richter<sup>53</sup>,Samuli Ripatti<sup>101</sup>,Saulius Rocka<sup>113</sup>,Cecilie Roe<sup>117</sup>,Olav Roise<sup>118,119</sup>,Jonathan Rosand<sup>120</sup>,Jeffrey V.Rosenfeld<sup>121</sup>, Christina Rosenlund<sup>122</sup>, Guy Rosenthal<sup>61</sup>, Rolf Rossaint<sup>83</sup>, Sandra Rossi<sup>106</sup>,Daniel Rueckert<sup>67</sup>,Martin Rusnák<sup>123</sup>,Juan Sahuquillo<sup>112</sup>,Oliver Sakowitz<sup>96,124</sup>,Renan SanchezPorras<sup>124</sup>,Janos Sandor<sup>125</sup>,Nadine Schäfer<sup>87</sup>,Silke Schmidt<sup>126</sup>,Herbert Schoechl<sup>127</sup>,Guus Schoonman<sup>128</sup>,Rico FrederikSchou<sup>129</sup> Elisabeth Schwendenwein<sup>11</sup>,Charlie Sewalt<sup>70</sup>,Ranjit D.Singh<sup>107,108</sup>, Toril Skandsen<sup>130,131</sup>,Peter Smielewski<sup>32</sup>,Abayomi Sorinola<sup>132</sup>,Emmanuel Stamatakis<sup>53</sup>,Simon Stanworth<sup>45</sup>,Robert Stevens<sup>133</sup>,William Stewart<sup>134</sup>,Ewout W.Steyerberg<sup>4,70,135</sup>, Nino Stocchetti<sup>3,136</sup>,Nina Sundström<sup>137</sup>,Riikka Takala138,Viktória Tamás132,Tomas Tamosuitis139,Mark StevenTaylor25, Braden TeAo<sup>58</sup>, Olli Tenovuo<sup>110</sup>, Alice Theadom<sup>58</sup>, Matt Thomas<sup>93</sup>, Dick Tibboel<sup>140</sup>, Marjolein Timmers<sup>80</sup>, Christos Tolias<sup>141</sup>, Tony Trapani<sup>34</sup>, Cristina MariaTudora<sup>99</sup>, Andreas Unterberg<sup>96</sup>,Peter Vajkoczy<sup>142</sup>,Shirley Vallance<sup>34</sup>,Egils Valeinis<sup>66</sup>,Zoltán Vámos<sup>56</sup>,Mathieu vander Jagt<sup>143</sup>, Gregory Vander Steen<sup>4</sup> Joukje vander Naalt<sup>77</sup>, Jeroen T. J. M. vanDijck<sup>107,108</sup>, Inge A. vanErp<sup>107,108</sup>, Thomas A.van Essen<sup>107,108</sup>,Wim VanHecke<sup>144</sup>, Caroline vanHeugten<sup>48</sup>, Dominique VanPraag<sup>145</sup>, Ernest vanVeen<sup>70</sup>, Thijs VandeVyvere<sup>144</sup>, Roel P. J. vanWijk<sup>107,108</sup>, Alessia Vargiolu<sup>38</sup>, Emmanuel Vega<sup>89</sup>, Kimberley Velt<sup>70</sup>, Jan Verheyden144,Paul M.Vespa146, Anne Vik130,147,Rimantas Vilcinis139,Victor Volovici<sup>73</sup>,Nicole vonSteinbüchel<sup>44</sup>, Daphne Voormolen<sup>70</sup>,Petar Vulekovic<sup>52</sup>,Kevin K. W. Wang<sup>148</sup>, Daniel Whitehouse<sup>53</sup>, Eveline Wiegers<sup>70</sup>,Guy Williams<sup>53</sup>,Lindsay Wilson<sup>75</sup>, Stefan Winzeck<sup>53</sup>, Stefan Wolf<sup>149</sup>, Zhihui Yang<sup>120</sup>,Peter Ylén<sup>150</sup>,Alexander Younsi<sup>96</sup>,Frederick A.Zeiler<sup>53,151</sup>, Veronika Zelinkova<sup>25</sup>, Agate Ziverte<sup>66</sup>, Tommaso Zoerle<sup>33</sup>

<sup>1</sup>Section ofPerioperative Medicine and Intensive Care, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden<sup>2,\*</sup>School ofElectrical Engineering and Computer Science, KTH Royal Institute of Technology, Stockholm, Sweden<sup>3</sup>NeuroscienceIntensive Care Unit, Department of Pathophysiology and Transplants, FondazioneIRCCS Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy<sup>4</sup>Departmentof Biomedical Data Sciences, Leiden UniversityMedical Center, Leiden, The Netherlands<sup>5</sup> Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK<sup>6</sup>Centre forArtificial Intelligence in Medicine, University of Cambridge, Cambridge, UK<sup>7</sup> János Szentágothai Research Centre, University of Pécs, Pécs, Hungary<sup>8</sup> Division of Surgery and Clinical Neuroscience, Department ofPhysical Medicine and Rehabilitation, OsloUniversity Hospital and University of Oslo, Oslo, Norway<sup>9</sup>Departmentof Neurosurgery, University Hospital Northern Norway,Tromso, Norway<sup>10</sup>Departmentof Physical Medicine and Rehabilitation, University Hospital Northern Norway, Tromso, Norway11TraumaSurgery, Medical University Vienna, Vienna, Austria12Departmentof Anesthesiology and Intensive Care, UniversityHospital Nancy, Nancy, France<sup>13</sup>RaymondPoincare Hospital, Assistance Publique – Hopitaux de Paris,Paris, France14Departmentof Anesthesiology and Intensive Care, S RaffaeleUniversity Hospital, Milan, Italy<sup>15</sup>Departmentof Neurosurgery, Radboud University Medical Center, Nijmegen, TheNetherlands<sup>16</sup>Departmentof Neurosurgery, University of Szeged, Szeged, Hungary<sup>17</sup>InternationalProjects Management, ARTTIC, Munchen, Germany<sup>18</sup>NeurologicalIntensive Care Unit, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria19Departmentof Neurosurgery and Anesthesia and Intensive Care Medicine, Karolinska University Hospital, Stockholm, Sweden<sup>20</sup>NIHRSurgical Reconstruction and Microbiology Research Centre, Birmingham,

UK<sup>21</sup> Anesthesie-Réanimation, Assistance Publique – Hopitaux de Paris, Paris, France22Departmentof Anesthesia and ICU, AOU Città dellaSalute e della Scienza di Turin – Orthopedic and Trauma Center, Turin, Italy<sup>23</sup>Department of Neurology, Odense University Hospital, Odense,Denmark24BehaviourWorksAustralia, Monash Sustainability Institute, Monash University, Victoria, Australia<sup>25</sup>Departme ntof Public Health, Faculty of Health Sciences and SocialWork, Trnava University, Trnava, Slovakia<sup>26</sup>QuesgenSystems Inc., Burlingame, CA, USA<sup>27</sup>Departmentof Epidemiology and Preventive Medicine, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine,Monash University, Melbourne, Australia<sup>28</sup>Departmentof Surgery and Perioperative Science, UmeåUniversity, Umeå, Sweden<sup>29</sup>Departmentof Neurosurgery, Medical School, University of Pécs, Pécs, Hungary<sup>30</sup>NeurotraumaResearch Group, János Szentágothai Research Centre, University of Pécs, Pécs, Hungary<sup>31</sup>Departmentof Medical Psychology, UniversitätsklinikumHamburg-Eppendorf, Hamburg, Germany<sup>32</sup> BrainPhysics Lab, Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK33Neuro ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy34Departmentof Epidemiology and Preventive Medicine, ANZIC Research Centre, MonashUniversity, Melbourne, VIC, Australia<sup>35</sup>Departmentof Neurosurgery, Hospital of Cruces, Bilbao, Spain<sup>36</sup>NeuroIntensiveCare, Niguarda Hospital, Milan, Italy<sup>37</sup>School ofMedicine and Surgery, Università Milano Bicocca, Milan, Italy<sup>38</sup>NeuroIntensiveCare, ASST di Monza, Monza, Italy<sup>39</sup>Department of Neurosurgery, Medical Faculty RWTHAachen University, Aachen, Germany40Departmentof Anesthesiology and Intensive CareMedicine,University Hospital Bonn, Bonn, Germany<sup>41</sup>Department of Anesthesia and Neurointensive Care, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK42School ofPublic Health and PM, The Alfred Hospital, Monash University, Melbourne, VIC, Australia<sup>43</sup>Radiology/MRIDepartment, MRC Cognition and Brain Sciences Unit,Cambridge, UK<sup>44</sup>Instituteof Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen, Göttingen,Germany45Oxford University Hospitals NHS Trust, Oxford, UK<sup>46</sup>IntensiveCare Unit, CHU Poitiers, Potiers, France<sup>47</sup>CriticalCare Directorate, University of Manchester NIHR BiomedicalResearch Centre, Salford Royal HospitalNHS Foundation Trust, Salford, UK48MovementScience Group, Faculty of Health and Life Sciences,Oxford Brookes University, Oxford, UK<sup>49</sup>Departmentof Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium<sup>50</sup>Departmentof Anesthesia and Intensive Care, Maggiore DellaCarità Hospital, Novara, Italy<sup>51</sup>Departmentof Neurosurgery, University Hospitals Leuven, Louvain, Belgium<sup>52</sup>Departmentof Neurosurgery, Faculty of Medicine, Clinical Centre of Vojvodina, University of Novi Sad, Novi Sad, Serbia53Division ofAnaesthesia, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK<sup>54</sup>Center forStroke Research Berlin, Berlin Institute ofHealth, Charité – UniversitätsmedizinBerlin, Freie Universität Berlin, Humboldt-Universität Zu Berlin,Berlin, Germany<sup>55</sup>IntensiveCare Unit, CHR Citadelle, Liège, Belgium<sup>56</sup>Departmentof Anaesthesiology and Intensive Therapy, University of Pécs, Pécs,Hungary<sup>57</sup>Departmentsof Neurology, Clinical Neurophysiology and Neuroanesthesiology,Region Hovedstaden Rigshospitalet, Copenhagen, Denmark58NationalInstitute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Studies, Auckland University of Technology, Auckland, NewZealand59Departmentof Neurology, Erasmus MC, Rotterdam, TheNetherlands<sup>60</sup>Departmentof Anesthesiology and Intensive Care, UniversityHospital Northern Norway, Tromso,Norway<sup>61</sup>Departmentof Neurosurgery, Hadassah-Hebrew University MedicalCenter, Jerusalem, Israel<sup>62</sup>Fundación InstitutoValenciano de Neurorrehabilitación (FIVAN), Valencia, Spain<sup>63</sup>Departmentof Neurosurgery, Shanghai Renji Hospital, Shanghai Jiaotong University/School of Medicine, Shanghai, China<sup>64</sup>KarolinskaInstitutet, INCF International NeuroinformaticsCoordinating Facility, Stockholm,Sweden<sup>65</sup>Emerg encyDepartment, CHU, Liège, Belgium<sup>66</sup>NeurosurgeryClinic, Pauls Stradins Clinical UniversityHospital, Riga, Latvia<sup>67</sup>Departmentof Computing, Imperial College London, London, UK<sup>68</sup>Departmentof Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain<sup>69</sup>Departmentof Anesthesia, Critical Care and Pain Medicine, Medical University of Vienna, Vienna, Austria70Departmentof Public Health, Erasmus Medical Center-UniversityMedical Center, Rotterdam, The Netherlands<sup>71</sup>College of Health and Medicine, Australian National University, Canberra, Australia72Departmentof Neurosurgery, Neurosciences Centre and JPN Apex Trauma Centre, All IndiaInstitute of Medical Sciences, New Delhi,110029, India<sup>73</sup>Department ofNeurosurgery, Erasmus MC, Rotterdam, TheNetherlands74Departmentof Neurosurgery, Oslo University Hospital, Oslo, Norway<sup>75</sup>Division ofPsychology, University of Stirling, Stirling, UK<sup>76</sup>Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital, Universityof Cambridge, Cambridge,

UK77Departmentof Neurology, University Medical Center Groningen,University of Groningen, Groningen, TheNetherlands<sup>78</sup>NeurointensiveCare, Sheffield Teaching Hospitals NHSFoundation Trust, Sheffield, UK79SalfordRoyal Hospital NHS Foundation Trust Acute Research Delivery Team, Salford, UK<sup>80</sup>Departmentof Intensive Care and Department of Ethics and Philosophy of Medicine, Erasmus Medical Center, Rotterdam, The Netherlands<sup>81</sup>Departmentof Clinical Neuroscience, Neurosurgery, UmeåUniversity, Umeå, Sweden<sup>82</sup>HungarianBrain Research Program – Grant No. KTIA\_13\_NAP-A-II/8, University of Pécs, Pécs,Hungary<sup>83</sup>Departmentof Anaesthesiology, University Hospital of Aachen, Aachen, Germany<sup>84</sup>CyclotronResearch Center, University of Liège, Liège, Belgium<sup>85</sup>Centre for Urgent and Emergency Care Research (CURE), Health Services Research Section, Schoolof Health and Related Research (ScHARR), Universityof Sheffield, Sheffield, UK<sup>86</sup>EmergencyDepartment, Salford Royal Hospital, Salford UK<sup>87</sup>Instituteof Research in Operative Medicine (IFOM), Witten/ Herdecke University, Cologne,Germany<sup>88</sup>VP GlobalProject Management CNS, ICON, Paris, France<sup>89</sup>Departmentof Anesthesiology-Intensive Care, Lille University Hospital,Lille, France<sup>90</sup>Departmentof Neurosurgery, Rambam Medical Center, Haifa, Israel<sup>91</sup> Departmentof Anesthesiology and Intensive Care, UniversityHospitals Southhampton NHS Trust,

Southhampton, UK<sup>92</sup>Departmentof Traumatology, Cologne-Merheim Medical Center (CMMC),Orthopedic Surgery and Sportmedicine, Witten/Herdecke University, Cologne, Germany<sup>93</sup> IntensiveCare Unit, Southmead Hospital, Bristol, Bristol, UK<sup>94</sup>Departmentof Neurological Surgery, University ofCalifornia, San Francisco, CA, USA<sup>95</sup>Departmentof Anesthesia and Intensive Care, M. BufaliniHospital, Cesena, Italy<sup>96</sup>Departmentof Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany<sup>97</sup>Departmentof Neurosurgery, The Walton centre NHS Foundation Trust, Liverpool, UK<sup>98</sup>Departmentof Medical Genetics, University of Pécs, Pécs, Hungary<sup>99</sup>Departmentof Neurosurgery, Emergency County Hospital Timisoara,Timisoara, Romania100School ofMedical Sciences, Örebro University, Örebro, Sweden<sup>101</sup>Institutefor Molecular Medicine Finland, University of Helsinki, Helsinki, Finland<sup>102</sup>Analyticand Translational Genetics Unit, Department ofMedicine; Psychiatric andNeurodevelopmental Genetics Unit, Departmentof Psychiatry, Department of Neurology,Massachusetts General Hospital, Boston, MA,USA<sup>103</sup>Program inMedical and Population Genetics; The Stanley Centerfor Psychiatric Research, The BroadInstitute of MIT and Harvard, Cambridge,MA, USA104Departmentof Radiology, University of Antwerp, Edegem, Belgium<sup>105</sup>Departmentof Anesthesiology and Intensive Care, UniversityHospital of Grenoble, Grenoble, France<sup>106</sup>Departmentof Anesthesia and Intensive Care, Azienda OspedalieraUniversità di Padova, Padua, Italy<sup>107</sup>Departmentof Neurosurgery, Leiden University Medical Center,Leiden, The Netherlands<sup>108</sup>Departmentof Neurosurgery, Medical Center Haaglanden, The Hague, TheNetherlands<sup>109</sup>Departmentof Neurosurgery, Helsinki University Central Hospital,Helsinki, Finland<sup>110</sup>Division ofClinical Neurosciences, Department ofNeurosurgery and Turku Brain Injury Centre, Turku University Hospital, Universityof Turku, Turku, Finland<sup>111</sup>Departmentof Anesthesiology and Critical Care, Pitié -Salpêtrière Teaching Hospital,Assistance Publique, Hôpitaux de Paris and University Pierreet Marie Curie, Paris,

France<sup>112</sup>Neurotraumatologyand Neurosurgery Research Unit (UNINN), Vall d'HebronResearch Institute, Barcelona, Spain<sup>113</sup>Departmentof Neurosurgery, Kaunas University of Technology andVilnius University, Vilnius, Lithuania114Departmentof Neurosurgery, Rezekne Hospital, Rēzekne, Latvia<sup>115</sup>Departmentof Anaesthesia, Critical Care and Pain Medicine NHSLothian, University of Edinburg, Edinburgh, UK116MRCBiostatistics Unit, Cambridge Institute of Public Health,Cambridge, UK<sup>117</sup>Departmentof Physical Medicine and Rehabilitation, Oslo University Hospital, Universityof Oslo, Oslo, Norway118Division ofOrthopedics, Oslo University Hospital, Oslo, Norway119Institute of Clinical Medicine,Faculty of Medicine, University of Oslo, Oslo, Norway120Broad Institute, MassachusettsGeneral Hospital, Cambridge MA Harvard Medical School,Boston MA,USA<sup>121</sup>National Trauma Research Institute, The Alfred Hospital, Monash University, Melbourne,VIC, Australia122Departmentof Neurosurgery, Odense University Hospital, Odense, Denmark<sup>123</sup>InternationalNeurotrauma Research Organisation, Vienna,

Austria124Klinik FürNeurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany125Division ofBiostatistics and Epidemiology, Department ofPreventive Medicine, University ofDebrecen, Debrecen, Hungary<sup>126</sup>DepartmentHealth and Prevention, UniversityGreifswald, Greifswald, Germany<sup>127</sup>Departmentof Anaesthesiology and Intensive Care, AUVA TraumaHospital, Salzburg, Austria128Departmentof Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, TheNetherlands<sup>129</sup>Departmentof Neuroanesthesia and Neurointensive Care, Odense University Hospital, Odense,Denmark130Departmentof Neuromedicine and Movement Science, NorwegianUniversity of Science and Technology,

NTNU, Trondheim, Norway<sup>131</sup> Departmentof Physical Medicine and Rehabilitation, St. Olavs Hospital, TrondheimUniversity Hospital, Trondheim, Norway132Departmentof Neurosurgery, University of Pécs, Pécs, Hungary133Division ofNeuroscience Critical Care, John Hopkins UniversitySchool of Medicine, Baltimore, USA134Departmentof Neuropathology, Queen Elizabeth University Hospital and University of Glasgow, Glasgow, UK<sup>135</sup>Deptartmentof Department of Biomedical Data Sciences, Leiden University Medical Center, Leid en,TheNetherlands<sup>136</sup>Departmentof Pathophysiology and Transplantation, NeuroscienceICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan University, Milan, Italy<sup>137</sup>Departmentof Radiation Sciences, BiomedicalEngineering, Umeå University, Umeå, Sweden<sup>138</sup>IntensiveCare Medicine and Pain Management, PerioperativeServices, Turku University Hospital, Universityof Turku, Turku, Finland<sup>139</sup>Departmentof Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania<sup>140</sup>IntensiveCare and Department of Pediatric Surgery, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam,The Netherlands141Departmentof Neurosurgery, Kings College London, London, UK<sup>142</sup>Neurologie, Neurochirurgie und Psychiatrie, Charité –Universitätsmedizin Berlin, Berlin,Germany143Departmentof Intensive Care Adults, Erasmus MC–University Medical Center Rotterdam, Rotterdam, The Netherlands<sup>144</sup>IcometrixNV, Louvain, Belgium<sup>145</sup>PsychologyDepartment, Antwerp University Hospital, Edegem, Belgium<sup>146</sup>Director ofNeurocritical Care, University of California, Los Angeles, USA<sup>147</sup>Departmentof Neurosurgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway148Departmentof Emergency Medicine, University ofFlorida, Gainesville, FL, USA<sup>149</sup>Departmentof Neurosurgery, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Freie Universität Berlin,Humboldt-Universität Zu Berlin, Berlin, Germany<sup>150</sup>VTTTechnical Research Centre, Tampere, Finland<sup>151</sup>Section ofNeurosurgery, Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB,Canada

#### **Author contributions**

AH, AE and DN undertook the primary supervision of the project. NS, ES, DM, DN took part in funding acquisition. CÅ, AE and DN were involved in data curation. CÅ, AH, AE and DN prepared the draft manuscript. CÅ and AH did the analyses and prepared the script used for the analyses. All authors read and approved the fnal manuscript.

#### **Funding**

Open access funding provided by Karolinska Institute. CENTER-TBI was supported by the European Union 7<sup>th</sup> Framework program (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), from OneMind (USA) and from Integra LifeSciences Corporation (USA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## **Availability of data and materials**

CENTER-TBI encourages data sharing, and there is a data sharing statement published. Data will be made available to researchers who provide a study proposal that is approved by the management committee to achieve the aims in the approved proposal. Proposals can be submitted online at [https://www.](https://www.center-tbi.eu/data/sharing) [center-tbi.eu/data/sharing](https://www.center-tbi.eu/data/sharing). A data access agreement is required, and all access must comply with regulatory restrictions imposed on the original study.

## **Declarations**

## **Ethics approval and consent to participate**

This sub-study was approved by the CENTER-TBI management committee. The CENTER-TBI study was conducted in accordance with all relevant laws of the European Union if directly applicable or of direct efect and all relevant laws of the country where the Recruiting sites were located, including but not limited to, the relevant privacy and data protection laws and regulations (the "Privacy Law"), the relevant laws and regulations on the use of human materials, and all relevant guidance relating to clinical studies from time to time in force including, but not limited to, the ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) ("ICH GCP") and the World Medical Association Declaration of Helsinki. Informed Consent by the patients or next of kin was obtained, according to the local legislations, for all patients recruited in the Core Dataset of CENTER-TBI and documented in the electronic case report form. Ethical approval for CENTER-TBI was obtained at

each recruiting site. The list of sites, Ethical Committees, approval numbers and approval dates are available online [\[34\]](#page-15-1).

## **Consent for publication**

Not applicable.

#### **Competing interests**

DM reports grants, personal fees and non-fnancial support from GlaxoSmithKline, grants and personal fees from NeuroTrauma Sciences, personal fees from Pfzer Ltd, personal fees from PressuraNeuro, grants and personal fees from Lantmannen AB, grants and personal fees from Integra, outside the submitted work. All other authors declare no competing interests.

#### **Author details**

<sup>1</sup> Section of Perioperative Medicine and Intensive Care, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. 2 <sup>2</sup>School of Electrical Engineering and Computer Science, KTH Royal Institute of Technology, Stockholm, Sweden. <sup>3</sup>Neuroscience Intensive Care Unit, Department of Pathophysiology and Transplants, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. <sup>4</sup>Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands. <sup>5</sup> Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK. <sup>6</sup>Centre for Artificial Intelligence in Medicine, University of Cambridge, Cambridge, UK.

#### Received: 20 February 2022 Accepted: 2 July 2022 Published online: 27 July 2022

#### **References**

- <span id="page-14-0"></span>1. Rubiano AM, Carney N, Chesnut R, Puyana JC. Global neurotrauma research challenges and opportunities. Nature. 2015;527(7578):S193–7.
- <span id="page-14-1"></span>2. Roozenbeek B, Maas AIR, Menon DK. Changing patterns in the epidemiology of traumatic brain injury. Nat Rev Neurol. 2013;9(4):231–6.
- Bragge P, Synnot A, Maas AI, Menon DK, Cooper DJ, Rosenfeld JV, et al. A state-of-the-science overview of randomized controlled trials evaluating acute management of moderate-to-severe traumatic brain injury. J Neurotrauma. 2016;33(16):1461–78.
- <span id="page-14-2"></span>4. Steyerberg EW, Wiegers E, Sewalt C, Buki A, Citerio G, De Keyser V, et al. Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study. Lancet Neurol. 2019;18(10):923–34.
- <span id="page-14-3"></span>5. Chesnut RM, Temkin N, Carney N, Dikmen S, Rondina C, Videtta W, et al. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med. 2012;36726367(27):2471–81.
- <span id="page-14-4"></span>6. Huijben JA, Wiegers EJA, Lingsma HF, Citerio G, Maas AIR, Menon DK, et al. Changing care pathways and between-center practice variations in intensive care for traumatic brain injury across Europe: a CENTER-TBI analysis. Intensive Care Med. 2020;46(5):995–1004.
- <span id="page-14-5"></span>7. Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GWJ, Bell MJ, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery [Internet]. 2016 [cited 2017 Oct 26]; Available from: [www.neurosurgery-online.com](http://www.neurosurgery-online.com)
- 8. Newcombe VFJ, Chow A. The features of the typical traumatic brain injury patient in the ICU are changing: what will this mean for the intensivist ? Curr Opin Crit Care. 2021;27:80.
- <span id="page-14-6"></span>9. Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017;16(12):987–1048.
- <span id="page-14-12"></span>10. Maas AIR, Menon DK, Steyerberg EW, Citerio G, Lecky F, Manley GT, et al. Collaborative European neurotrauma efectiveness research in traumatic brain injury (CENTER-TBI): a prospective longitudinal observational study. Neurosurgery. 2015;76:67–80.
- <span id="page-14-7"></span>11. Tenovuo O, Diaz-Arrastia R, Goldstein LE, Sharp DJ, van der Naalt J, Zasler ND. Assessing the severity of traumatic brain injury—time for a change? J Clin Med. 2021;10(1):148.
- <span id="page-14-8"></span>12. Kuruvilla ME, Lee FEH, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–33.
- <span id="page-14-9"></span>13. Prescott HC, Calfee CS, Taylor Thompson B, Angus DC, Liu VX. Toward smarter lumping and smarter splitting: rethinking strategies for sepsis

and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med. 2016;194(2):147–55.

- <span id="page-14-10"></span>14. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, et al. Latent class analysis of ARDS subphenotypes: analysis of data from two randomized controlled trials. Lancet Respir Med. 2014;2:611–20.
- <span id="page-14-11"></span>15. Antclife DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, et al. Transcriptomic signatures in sepsis and a diferential response to steroids. From the VANISH randomized trial. Am J Respir Crit Care Med. 2019;199(8):980–6.
- <span id="page-14-13"></span>16. Steyerberg EW, Mushkudiani N, Perel P, Butcher I, Lu J, Mchugh GS, et al. Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics. 2008 [cited 2018 May 24]; Available from: http://journals. plos.org/plosmedicine/article/fle?id=[https://doi.org/10.1371/journal.](https://doi.org/10.1371/journal.pmed.0050165&type=printable) [pmed.0050165&type](https://doi.org/10.1371/journal.pmed.0050165&type=printable)=printable
- <span id="page-14-14"></span>17. R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2018. Available from: <https://www.r-project.org/>
- <span id="page-14-15"></span>18. Wei T, Simko V, Levy M, Xie Y, Jin Y, Zemla J. R package "corrplot": visualization of a correlation matrix. Statistician. 2017;56:316–24.
- <span id="page-14-16"></span>19. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. J Roy Stat Soc Ser B (Methodol). 1977;39(1):1–22.
- <span id="page-14-17"></span>20. Holst A. The use of a bayesian neural network model for classifcation tasks. [Internet]. 1997 p. 172. Available from: oai:DiVA.org:su-61748
- <span id="page-14-18"></span>21. Lange T, Roth V, Braun ML, Buhmann JM. Stability-based validation of clustering solutions. Neural Comput. 2004;16(6):1299–323.
- <span id="page-14-19"></span>22. van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1–67.
- <span id="page-14-20"></span>23. Hyam JA, Welch CA, Harrison DA, Menon DK. Case mix, outcomes and comparison of risk prediction models for admissions to adult, general and specialist critical care units for head injury: a secondary analysis of the ICNARC case mix programme database. Crit Care. 2006;10(Suppl 2):S2.
- <span id="page-14-21"></span>24. Raj R, Skrifvars MB, Bendel S, Selander T, Kivisaari R, Siironen J, et al. Predicting six-month mortality of patients with traumatic brain injury: usefulness of common intensive care severity scores. Crit Care. 2014;18(2):1–9.
- <span id="page-14-22"></span>25. Folweiler KA, Sandsmark DK, Diaz-Arrastia R, Cohen AS, Masino AJ. Unsupervised machine learning reveals novel traumatic brain injury patient phenotypes with distinct acute injury profles and long-term outcomes. J Neurotrauma. 2020;1444:1431–44.
- <span id="page-14-23"></span>26. Gravesteijn BY, Sewalt CA, Ercole A, Akerlund C, Nelson D, Maas AIR, et al. Toward a new multi-dimensional classifcation of traumatic brain injury: a collaborative european neurotrauma efectiveness research for traumatic brain injury study. J Neurotrauma. 2020;37(7):1002–10.
- <span id="page-14-24"></span>27. Yuh EL, Jain S, Sun X, Pisică D, Harris MH, Taylor SR, et al. Pathological computed tomography features associated with adverse outcomes after mild traumatic brain injury: A TRACK-TBI study with external validation in CENTER-TBI. JAMA Neurol. 2021;78(9):1137–48.
- <span id="page-14-25"></span>28. Maas AIR, Hukkelhoven CWPM, Marshall LF, Steyerberg EW. Prediction of outcome in traumatic brain injury with computed tomographic characteristics: a comparison between the computed tomographic classifcation and combinations of computed tomographic predictors. Neurosurgery. 2005;57(6):1173–81.
- 29. Thelin EP, Nelson DW, Vehviläinen J, Nyström H, Kivisaari R, Siironen J, et al. Evaluation of novel computerized tomography scoring systems in human traumatic brain injury: an observational, multicenter study. PLoS Med. 2017;14(8):1–19.
- 30. Raj R, Siironen J, Skrifvars MB, Hernesniemi J, Kivisaari R. Predicting outcome in traumatic brain injury: development of a novel computerized tomography classifcation system (Helsinki Computerized Tomography Score). Neurosurgery. 2014;75(6):632–46.
- <span id="page-14-26"></span>31. Nelson DW, Nyström H, MacCallum RM, Thornquist B, Lilja A, Bellander BM, et al. Extended analysis of early computed tomography scans of traumatic brain injured patients and relations to outcome. J Neurotrauma. 2010;27(1):51–64.
- <span id="page-14-27"></span>32. Lingsma HF, Roozenbeek B, Steyerberg EW, Murray GD, Maas AI. Early prognosis in traumatic brain injury: from prophecies to predictions. Lancet Neurol. 2010;9(5):543–54.
- <span id="page-15-0"></span>33. Hawryluk GWJ, Aguilera S, Buki A, Bulger E, Citerio G, Cooper DJ, et al. A management algorithm for patients with intracranial pressure monitoring: the seattle international severe traumatic brain injury consensus conference (SIBICC). Intensive Care Med. 2019;45(12):1783–94.
- <span id="page-15-1"></span>34. CENTER-TBI. CENTER-TBI Ethical approval [Internet]. Available from: <https://www.center-tbi.eu/project/ethical-approval>

## **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.

## Ready to submit your research? Choose BMC and benefit from:

- **•** fast, convenient online submission
- **•** thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- **•** gold Open Access which fosters wider collaboration and increased citations
- **•** maximum visibility for your research: over 100M website views per year

#### **At BMC, research is always in progress.**

**Learn more** biomedcentral.com/submissions

